CD274 and non-small cell lung carcinoma: Pembrolizumab monotherapy has been established as a standard first‐line treatment for NSCLC with PD‐L1 expression of ≥50% and no oncogenic driver mutations, based on astonishing increases in OS and PFS, relative to platinum doublet chemotherapy.5